

Complementary Summary Supporting the Announcements of the Agreement to Acquire Rioux Vision, Inc. and of Singlepointe

This complementary financial and statistical information will include forward-looking statements subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. For a more detailed description of the risks that impact these forward-looking statements, please refer to the information under the heading "Risk Factors" and under the heading "Management's Discussion and analysis of financial condition and results of operations" in the Omnicell annual report on Form 10-K filed with the SEC on March 23, 2007, as well our more recent filings with the SEC. Please be aware that you should not place undue reliance on any forward-looking statements made today.

This is a complementary summary of a call Omnicell arranged to discuss an announcement made last Friday, November 30, 2007 regarding the company's signed agreement to acquire Rioux Vision and Omnicell's announcement of SinglePointe™, a significant new medication management solution. Press releases announcing the Rioux acquisition and SinglePointe can be found on Omnicell's website at www.omnicell.com.

Announcement Highlights

We're excited to announce two very significant steps in the company's strategy to provide the ability for clinicians to control up to 100% of the medications used in acute care facilities.

SinglePointe Patient-specific Automated Medication Management Solution

First, today Omnicell announced SinglePointe, the industry's first total patient specific automated medication management solution. SinglePointe, which is a feature of the Omnicell release 12.0 software, allows nursing and pharmacy staff to store, manage, and track patient specific medications, creating a closed loop distribution system that greatly reduces the risk of medication errors and boosts staff efficiency. SinglePointe is a departure from medication dispensing systems that are designed to manage an inventory of commonly used medications and record when those medications are dispensed for administration to a patient. SinglePointe enhances these systems by providing an intuitive workflow that allows specialty medications not normally stocked in the dispensing system to be stocked in a portion of the system assigned specifically to an individual patient. This provides nurses with a single point of access for all patient medications and provides the hospital pharmacy with one medication management process. SinglePointe addresses all aspects of the medication-use process: New medication orders, changes to orders, patient transfers, and patient discharges. We believe addressing all these areas will reduce the occurrence of missing doses, those times when a nurse cannot find the dose needed by a patient. And it not only allows for automated tracking of drugs not normally stocked in the dispensing system, but also allows for the tracking of multi-use items such as inhalers, creams, and drops, as well as medications brought by the patient from home. SinglePointe will dynamically reassign stocking locations in the dispensing system as patients transfer or are discharged. Today, medication dispensing systems typically stock drugs that represent about 80% of the medications used in acute care facilities. The addition of SinglePointe closes the remaining 20% gap in medication management, allowing medication dispensing systems to stock up to 100% of the medications used, bringing a new level of control and safety to the medication

distribution process and significantly reducing missing doses. Dangerous and inefficient manual processes and workarounds can be virtually eliminated. SinglePointe can be implemented without changing any hardware on an existing OmniRx® system, preserving and extending the value of our customer's investment. SinglePointe will be an individually priced feature of our 12.0 software and we expect to ship in summer 2008.

SinglePointe is one of 25 new features inspired by Omnicell customers that have been incorporated into Omnicell release 12.0. Another new feature allows a pharmacist to prohibit certain medications from being stocked in specific dispensing systems. With this feature, a hospital could prohibit an adult dose of a medication from being stocked in a system that supports a pediatric unit. This feature, added to our barcode safety features, would virtually eliminate unfortunate errors like the ones recently reported in the news where infants received adult doses of medications. With release 12.0, Omnicell medication dispensing systems provide safety features that are unmatched in the industry.

Agreement to Acquire Rioux Vision, Inc.

The second significant announcement in the company's strategy to provide control of 100% of the medications, and 100% of the medication administration process, is an announcement last week of the agreement to acquire Rioux Vision, Inc, a privately-held developer and manufacturer of mobile carts for acute care facilities. Rioux Vision mobile cart technologies, such as the recently announced 'Rio' product line, are fully-integrated into the bedside point-of-care environment, enabling nurses to have easy access to patient records and electronically integrate record keeping into the patient care process. The Rio product line offers a removable medication distribution cart option and features multiple individually locking drawer configurations. The system also features a removable, exchangeable power management system and software.

Today, the Rio mobile cart system includes a computer that operates customer owned hospital information systems. Over the next year, Omnicell intends to integrate the Rio mobile cart technology with the Omnicell 12.0 medication control software and our existing bedside verification software, SafetyMed™. This creates a fully integrated medication management and control system that seamlessly flows from the automated dispensing system, to the mobile cart, to the patient bedside, with no lapse in patient safety. The addition of patient-specific medication management software in a mobile cart significantly extends the Omnicell product line and provides a platform for total control of medications to the patient's bedside. Omnicell intends to begin shipping a version of the Rio mobile cart, integrated with Omnicell medication control systems, in the second half of 2008. The company also intends to continue to market the current version of the Rio mobile cart solution.

Customers told us they needed a way to manage all their medications. Customers told us they needed a mobile medication solution. We listened. By listening to our customers, we have developed a product suite that offers a complete solution to some of the most difficult problems and inefficiencies for hospital pharmacy and nursing staff, and helps them towards their goal of 100% medication management and increased patient safety.

SinglePointe extends our software solutions by providing the tools needed to manage all the drugs in an acute care setting, and Rioux Vision provides an advanced hardware platform that allows our software to be extended over a greater portion of the medication distribution process. Together, these two products, combined with Omnicell's existing product line, provide a complete solution to help clinicians reach their goal of 100% automated medication management and increased patient safety.

Financial Comments on the Rioux Vision announcement

Rioux Vision has signed an agreement to be acquired in an all cash transaction that Omnicell expects to close within the next month. The purchase price will be \$26 million, subject to adjustments for certain actual working capital positions upon the date of close. The financial results of Rioux Vision will be incorporated into Omnicell's financial results following the close of the transaction. Due to the potential for the close to be very late in 2007 we do not expect the effect on the Omnicell Q4 2007 results to be material. Approximately 60 Rioux Vision employees will be made offers to become Omnicell employees upon the close of the transaction. Omnicell will add a 40,000 square foot leased facility in Elgin, South Carolina and a smaller leased facility in Livermore, California to our current facilities. As part of the acquisition, Omnicell has agreed to assume defense against a patent claim on the design of a hinge on a monitor, which we consider to be non-material in nature. The acquisition of Rioux Vision will add approximately 200 customers to the company's customer base, and we will assume service and support of all existing Rioux Vision customers.

We expect the addition of Rioux Vision products to add \$10 to \$13 million, or 5-6% additional growth, to the Omnicell revenues in 2008. We had previously guided for 21% to 23% revenue growth in 2008 from 2007. With the addition of Rioux Vision products, we expect our revenue growth during 2008 to be 26% to 29% over 2007.

The purchase price of Rioux Vision will be allocated among assets, amortizable purchased intangibles, and goodwill. We expect a significant portion of the purchase price may be allocated to amortizable purchased intangibles. During 2008, we intend to integrate the Rioux Vision technology with the Omnicell medication management technology, which will require additional internal development effort. We will also initially expend effort to assure the Rioux Vision business is fully integrated with the Omnicell business so there is no lapse in the high quality solutions expected by our customers. We expect the initial expenses of the integration, including the amortizable purchase intangibles, will make the addition of the Rioux Vision business dilutive to earnings in 2008 by approximately \$0.05 per diluted share. We had previously guided to 2008 EPS of \$0.90 to \$0.93, excluding stock compensation charges. We now expect 2008 EPS to be \$0.85 to \$0.88 on a pro-forma Non-GAAP basis excluding stock compensation expenses. As a reminder, we continue to expect our 2008 GAAP tax rate to be 38%. We expect the acquisition to be EBITDA neutral in 2008.

At this time we are not providing specific guidance on the Omnicell financial results for 2009. However, following the integration of the Rioux Vision business in 2008, we expect the acquisition to continue to add revenue growth to our business and be accretive to 2009 earnings, generating positive EBITDA and cash flows.

Summary

We are very excited about the addition of the SinglePointe software and Rioux Vision mobile hardware platform to our suite of medication management solutions. Inspired by our customers and their needs, these are significant steps in 100% medication control and I am proud that Omnicell is at the forefront of these solutions.